FDA approves Foundation Medicine test for Wilserdly combination therapy
The FDA approved Foundation Medicine’s FoundationOne Liquid CDx as the first companion diagnostic for WILSERDLY (giredestrant) combined with everolimus. The test identifies adults with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer who may qualify for the combination.
1. Diagnostic approval
The FDA approved Foundation Medicine’s FoundationOne Liquid CDx as the first companion diagnostic for WILSERDLY (giredestrant) combined with everolimus. The test identifies adults with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer who may qualify for the treatment combination.





